In silicoScreening of Pyridoxine Carbamates for Anti-Alzheimer's Activities / Dnyaneshwar Baswar, Abha Sharma, Awanish Mishra
Background: Alzheimer’s disease (AD), an irreversible complex neurodegenerative disorder, is the most common type of dementia, with progressive loss of cholinergic neurons. Based on the multi-factorial etiology of Alzheimer’s disease, novel ligands strategy appears as an up-coming approach for the development of newer molecules against AD. This study is envisaged to investigate anti-Alzheimer’s potential of 10 synthesized compounds. The screening of compounds (1-10) was carried out using in silico techniques. Methods: For in silico screening of physicochemical properties of compounds, Molinspiration property engine v.2018.03, Swiss ADME online web-server and pkCSM ADME were used. For pharmacodynamic prediction, PASS software was used, while the toxicity profile of compounds was analyzed through ProTox-II online software. Simultaneously, molecular docking analysis was performed on mouse AChE enzyme (PDB ID:2JGE, obtained from RSCB PDB) using Auto Dock Tools 1.5.6. Results: Based on in silico studies, compound 9 and 10 have been found to have better druglikeness, LD50 value, better anti-Alzheimer’s, and nootropic activities. However, these compounds had poor blood-brain barrier (BBB) permeability. Compounds 4 and 9 were predicted with a better docking score for the AChE enzyme. Conclusion: The outcome of in silico studies has suggested, out of various substitutions at different positions of pyridoxine-carbamate, compound 9 has shown promising drug-likeness, with better safety and efficacy profile for anti-Alzheimer’s activity. However, BBB permeability appears as one of the major limitations of all these compounds. Further studies are required to confirm its biological activities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Central nervous system agents in medicinal chemistry - 21(2021), 1, Seite 39- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baswar, Dnyaneshwar [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL008972265 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL008972265 | ||
| 003 | DE-627 | ||
| 005 | 20231128163545.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220316s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL008972265 | ||
| 035 | |a (KFL)prod_DARH_.4A0600179FAC3CC9D8A52F169AB6CCF579997F16 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Baswar, Dnyaneshwar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In silicoScreening of Pyridoxine Carbamates for Anti-Alzheimer's Activities |c Dnyaneshwar Baswar, Abha Sharma, Awanish Mishra |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Alzheimer’s disease (AD), an irreversible complex neurodegenerative disorder, is the most common type of dementia, with progressive loss of cholinergic neurons. Based on the multi-factorial etiology of Alzheimer’s disease, novel ligands strategy appears as an up-coming approach for the development of newer molecules against AD. This study is envisaged to investigate anti-Alzheimer’s potential of 10 synthesized compounds. The screening of compounds (1-10) was carried out using in silico techniques. Methods: For in silico screening of physicochemical properties of compounds, Molinspiration property engine v.2018.03, Swiss ADME online web-server and pkCSM ADME were used. For pharmacodynamic prediction, PASS software was used, while the toxicity profile of compounds was analyzed through ProTox-II online software. Simultaneously, molecular docking analysis was performed on mouse AChE enzyme (PDB ID:2JGE, obtained from RSCB PDB) using Auto Dock Tools 1.5.6. Results: Based on in silico studies, compound 9 and 10 have been found to have better druglikeness, LD50 value, better anti-Alzheimer’s, and nootropic activities. However, these compounds had poor blood-brain barrier (BBB) permeability. Compounds 4 and 9 were predicted with a better docking score for the AChE enzyme. Conclusion: The outcome of in silico studies has suggested, out of various substitutions at different positions of pyridoxine-carbamate, compound 9 has shown promising drug-likeness, with better safety and efficacy profile for anti-Alzheimer’s activity. However, BBB permeability appears as one of the major limitations of all these compounds. Further studies are required to confirm its biological activities | ||
| 700 | 1 | |a Sharma, Abha |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Awanish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Central nervous system agents in medicinal chemistry |d Sharjah : Bentham Sc. Publ., 2006 |g 21(2021), 1, Seite 39- |h Online-Ressource |w (DE-627)KFL000006521 |w (DE-600)2254209-7 |w (DE-576)273891030 |x 1875-6166 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g pages:39- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5249&volume=21&issue=1&spage=39 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |h 39- | ||